Drug Interactions between cholera vaccine and Heartburn Relief
This report displays the potential drug interactions for the following 2 drugs:
- cholera vaccine
- Heartburn Relief (famotidine)
Interactions between your drugs
No interactions were found between cholera vaccine and Heartburn Relief. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
cholera vaccine
A total of 298 drugs are known to interact with cholera vaccine.
- Cholera vaccine is in the drug class bacterial vaccines.
- Cholera vaccine is used to treat Cholera Prophylaxis.
Heartburn Relief
A total of 314 drugs are known to interact with Heartburn Relief.
- Heartburn relief is in the drug class H2 antagonists.
- Heartburn relief is used to treat the following conditions:
Drug and food interactions
cholera vaccine food
Applies to: cholera vaccine
ADJUST DOSING INTERVAL: Coadministration of oral cholera vaccine with food or an oral beverage may impair its efficacy. The formulations of both the inactivated and live, attenuated oral cholera vaccines (Dukoral and Vaxchora, respectively) are acid-labile, and must be administered with a buffer. According to the manufacturer, eating and drinking may interfere with the protective effect of the buffer. However, clinical data are not available.
MANAGEMENT: It is recommended that patients avoid eating or drinking for 60 minutes before and after administration of either Dukoral or Vaxchora oral cholera vaccines.
References (4)
- (2023) "Product Information. Vaxchora (cholera vaccine, live)." Patientric Ltd
- (2022) "Product Information. Dukoral (cholera vaccine, inactivated)." Valneva Sweden AB
- (2023) "Product Information. Dukoral (cholera vaccine)." Valneva UK Ltd
- (2024) "Product Information. Vaxchora (cholera vaccine, live)." Emergent Travel Health, Inc
famotidine food
Applies to: Heartburn Relief (famotidine)
H2 antagonists may reduce the clearance of nicotine. Cimetidine, 600 mg given twice a day for two days, reduced clearance of an intravenous nicotine dose by 30%. Ranitidine, 300 mg given twice a day for two days, reduced clearance by 10%. The clinical significance of this interaction is not known. Patients should be monitored for increased nicotine effects when using the patches or gum for smoking cessation and dosage adjustments should be made as appropriate.
References (1)
- Bendayan R, Sullivan JT, Shaw C, Frecker RC, Sellers EM (1990) "Effect of cimetidine and ranitidine on the hepatic and renal elimination of nicotine in humans." Eur J Clin Pharmacol, 38, p. 165-9
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.